跳至主要内容
临床试验/NL-OMON29281
NL-OMON29281尚未招募不适用

The influence of CYP2C19 loss-of-function alleles on atherothrombotic events in patients on clopidogrel after endovascular aneurysm repair (EVAR)

ot applicable0 个研究点目标入组 300 人开始时间: 待定最近更新:
适应症

试验速览

阶段
不适用
状态
尚未招募
发起方
ot applicable
入组人数
300

研究概览

简要总结

ot applicable

研究设计

研究类型
Observational

入排标准

入选标准

  • Adult patients (age 18 years)
  • - Obtained written informed consent
  • - Patients with the ability to perform a buccal swab at home
  • - Patients who underwent EVAR for an infrarenal AAA between January 2016 and April 2020, including those that were additionally treated with an iliac branched device and/or coiling of the internal iliac artery
  • - Patients who are on continues treatment with clopidogrel as single antiplatelet therapy since EVAR

排除标准

  • - Patients with a known CYP2C19 genotype or metabolizer state
  • - Patients who are treated with other anticoagulants such as aspirin, ticagrelor, prasugrel, coumarins or Non vitamin K Oral Anti-Coagulants (NOACs)
  • - Patient treated for a juxtarenal AAA with Fenestrated EVAR, Chimney EVAR or open surgical repair
  • - Patients that have used clopidogrel only temporary after EVAR

研究者

发起方
ot applicable

相似试验

The influence of CYP2C19 loss-of-function alleles on... | 临床试验